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Cell death: Shadow Baxing
John Silke and David L. Vaux
Bcl-2, one of a family of key regulators of apoptosis,
was the first cell-death machinery component to be
identified, but how the family functions is still not clear.
Mammalian Bax, a pro-apoptotic family member, can
cause yeast cells to die, and two recent yeast genetic
screens shed light on how Bax might function.
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Bcl-2, the prototype of a rapidly growing family of pro-
teins, is able to inhibit cell death by preventing the activ-
ity of caspases, the proteases that are the key effector
molecules of apoptosis. Although some Bcl-2-like proteins
— Bcl-xL, for instance — inhibit apoptosis, other
members of the same family, such as Bax and Bak,
promote cell death. Given that Bax, the first pro-apoptotic
family member to be identified, was discovered as a
protein that could bind to Bcl-2 [1], it was initially pro-
posed that the pro-apoptotic members sequestered the
anti-apoptotic (pro-survival) members, thereby preventing
them from exercising their anti-apoptotic function.
Interactions between Bcl-2 family members occur via three
domains, referred to as Bcl-2 homology (BH) regions. BH1
(Figure 1a,b,d; khaki) is composed of parts of the central α
helices 5 and 6 (Figure 1c; red) and is essential for both the
heterodimerisation and the function of Bcl-2. The crystal
structure of the anti-apoptotic Bcl-xL [2] revealed that the
three conserved domains — BH1, BH2 and BH3 — form a
hydrophobic pocket that, in the case of Bcl-xL, binds
strongly to a BH3-containing peptide from Bak (Figure 1b,
purple) [3], a pro-apoptotic family member. Deletions
within the BH3 domain (Figure 1, orange) of pro-apoptotic
family members abolish their cytotoxic activity [4]. Fur-
thermore, and consistent with the idea of a major role for
the BH3 domain, BH3 peptides alone can kill cells, and a
subfamily of the pro-apoptotic molecules — Bid, Bik, Bad,
Figure 1
The relative positions of the conserved domains
in Bcl-xL, the only Bcl-2 family member for
which the crystal structure is known. BH1,
khaki; BH2, yellow; BH3, orange. (a) A
schematic of the Bcl-xL protein structure, and
an alignment of the BH domains from Bcl-xL,
Bcl-2, Bax and Bak. Deletions that did not
abolish the cytotoxic activity of Bax in yeast are
boxed in black; deletions that did abolish the
cytotoxicity of Bax and Bak in yeast are boxed
in red. Positions of the alpha helices are shown
as pink boxes. MA, membrane attachment
region; Loop, unstructured loop domain that is
not present in all Bcl-2 family members.
(b) Space-filling model of Bcl-xL binding to the
Bak BH3 peptide. The Bak peptide is shown
as a purple helix (using coordinates from [3]).
(c) Bcl-xL structure [2] with helix 5, bright red
and helix 6, paler red; also highlighted is part of
BH2 (yellow) and the whole of BH3 (orange).
(d) The same Bcl-xL structure [2] but showing
in gray the conserved amino acids from Bcl-xL
which, when deleted from Bax, did not abolish
cytotoxic activity of Bax in yeast (as boxed in
black in (a)); and in red the conserved amino
acids from Bcl-xL which, when deleted from
Bax, abolished the cytotoxicity of Bax in yeast
(as boxed in red in (a)). All images were
generated with RasMol2.6 [22]. Note that all
images show only the crystal structure of Bcl-
xL, and this structure can only be used to make
inferences about that of Bax or Bak.
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Hrk and Bim — have only a BH3 domain in common with
the rest of the Bcl-2 family. Some of the anti-apoptotic
homologs also have a BH4 region, which is essential both
for their pro-survival function and to allow them, when
overexpressed in mammalian cells, to interact (directly or
indirectly) with the Caenorhabditis elegans protein Ced-4, an
adaptor that activates the caspases [5]. 
Several mechanisms of action have been proposed for the
pro- and anti-apoptotic Bcl-2 family members. From genetic
studies in C. elegans, it seems that Ced-9, the nematode
Bcl-2 homolog, functions to prevent the adaptor Ced-4 from
activating the caspase Ced-3. Biochemical data suggest the
interactions between Ced-9, Ced-4 and Ced-3 are direct,
and analogous direct interactions occur in mammalian
systems to allow Bcl-xL to bind the Ced-4 homolog Apaf-1
and prevent it from activating pro-caspase 9 (Figure 2). 
The crystal structure of the anti-apoptotic Bcl-xL revealed
that Bcl-xL shares a common fold with certain pore-
forming molecules, including the membrane-translocating
subunit of diphtheria toxin [2]. This led to speculation that
proteins of the Bcl-2 family might act as pores or channels
in membranes such as the outer membrane of the mito-
chondrion, where around one third of the cell’s Bcl-2 is
located. Subsequent studies have shown that Bax has pore-
forming potential in vitro that can be inhibited by Bcl-2 [6].
Biochemical purification of Apaf-1 revealed that cyto-
chrome c is a molecule capable of activating a complex of
Apaf-1, dATP and pro-caspase 9. This finding led to the
proposal that Bcl-2 and Bcl-xL act by preventing the
release of cytochrome c from the mitochondria [7], while
Bax promotes cytochrome c release, leading to apoptosis
(Figure 2) [8]. But this model does not explain why Bcl-2
targeted to the endoplasmic reticulum is still able to
prevent apoptosis, nor why Bcl-2 can protect cells even
after cytochrome c has entered the cytoplasm [8,9].
Whatever the precise mechanism of action of Bcl-2 and
Bcl-xL, the simplest model for Bax function is that Bax
binds to and antagonises Bcl-2 and Bcl-xL. An alternative
proposal is that pro-apoptotic Bcl-2 family  proteins, such
as Bax and Bak, actively participate in the cell-killing
process but act through a caspase-independent mecha-
nism. This model stemmed from an observation that, at
least in one circumstance, Bax cytotoxicity in mammalian
cells was not inhibited by peptide inhibitors of caspase
activity [10], and observations that Bax or Bak was toxic
when expressed in the yeasts Saccharomyces cerevisiae
[11,12] or Schizosaccharomyces pombe [13], even though
neither organism appears to contain a caspase. 
The ability of Bax to kill yeast cells is significant for two
reasons: firstly, it allows Bax to be studied in cells that lack
caspases and other Bcl-2 family members, and secondly, it
allows the use of a genetic approach to determine Bax
function. Two recent publications (discussed below)
support the idea that Bax can kill independent of caspases
and other Bcl-2 family members. The key questions are
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Figure 2
Model for the roles of Bcl-2/Bcl-xL and Bax in
apoptosis. C denotes the CARD domain of
both Apaf-1 and caspase 9 (casp-9); Ced-4-
like indicates the Ced-4-like domain of Apaf-1
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how Bax kills yeast cells, and whether or not Bax behaves
in yeast the same way it does in mammalian cells. Bax
might kill yeast via some activity that is not related to its
function in mammalian cells. For example, while overex-
pression of the c-Src protein-tyrosine kinase transforms
mammalian cells, S. pombe expressing c-Src die, presum-
ably as a result of the inappropriate massive phosphoryla-
tion of tyrosines in yeast proteins [14]. 
Alternatively yeast-cell killing might reflect Bax acting by
targeting similar molecules in both yeast and mammalian
cells. Thus, for example, expression of the chimeric acti-
vator GAL4–VP16 is toxic to S. cerevisiae [15]: this
chimeric protein is such a potent activator of transcription
that it is able squelch yeast co-activators of transcription
that are necessary for survival. In a similar way, Bax might
bind to some conserved element which underlies its cyto-
toxic activity in both yeast and mammalian cells. This
explanation would be consistent with the one proven mol-
ecular aspect of Bax function, which is that it binds to
other proteins.
In some ways, Bax killing of yeast cells resembles Bax-
induced apoptosis of mammalian cells. As in mammalian
cells, Bax can associate with the mitochondria, and this
localisation requires its carboxy-terminal hydrophobic tail
in yeast. In both mammalian and yeast cells, Bax causes
release of cytochrome c from mitochondria [16], and co-
expression of Bcl-2 prevents Bax-induced killing. It
should be emphasised that the ability of Bcl-2 to protect
does not necessarily mean that Bax killing of yeast is
physiological, however, as Bcl-2 co-expression might
protect yeast by being a preferred partner for Bax,
thereby preventing a non-physiological cytotoxic activity.
In other ways Bax behaves differently in the two systems.
Bax probably only localises to mitochondria following a
death stimulus in mammalian cells [17], whereas it
appears to localise constitutively in yeast. Bax mutant
proteins lacking the hydrophobic tail are not cytotoxic in
yeast and do not localise to the mitochondria, whereas in
mammalian cells Bax does not require the tail for cyto-
toxicity, possibly because it can be localised to the mito-
chondria during the induction of cell death by binding to
other proteins. 
As Bax has the potential to form pores in vitro, it is possi-
ble that pore formation kills yeast by allowing release of
cytochrome c or by dissipation of the mitochondrial
membrane potential. Arguing against this possibility,
deletion of parts of the BH1 domain of Bax (Figure 1,
gray), which would presumably significantly disrupt one
of two central helices with membrane-spanning potential
(Figure 1c; helix 5, bright red, and helix 6, paler red),
does not inhibit Bax’s cytotoxicity in yeast [12]. The
same is true for deletions within BH2, although these
may not be so disruptive of the membrane-spanning
helix. In striking contrast, a four amino-acid deletion
within BH3 (Figure 1a,d, red), which is clearly distinct
from the membrane-spanning helices, completely abol-
ishes the cytotoxic activity of Bax in both yeast and mam-
malian cells. Similar results were obtained with Bak
(Figure 1a) [13]. These results imply that the BH3
domain of Bax, rather than the pore-forming region, is
the key to its cytotoxicity in both yeast and mammalian
cells. Of course, it remains entirely possible that the
mutation in BH3 completely disrupts the structure,
having indirect effects on the pore-forming region. 
Do the results of genetic screens in yeast provide any
further insight into Bax cytotoxicity? In the first screen
[18], the authors generated yeast mutants that were resis-
tant to Bax killing. Sensitivity to Bax could be restored
by co-expression of subunit 4 of the yeast F0F1 ATPase
(equivalent to subunit b of the animal mitochondrial
F0F1 ATPase) although, curiously, the actual mutation(s)
in the resistant yeast strain was not reported [18].
Oligomycin, a pharmacological inhibitor of the F0F1
ATPase, at the one concentration tested, conferred on
wild-type yeast partial resistance to Bax expression, and
yeast with a mutant δ subunit of the F0F1 ATPase were
completely resistant to Bax expression. As both subunits
4/b and δ are involved in joining the F0 to the F1 subunit,
perhaps the F0F1 connection is required for Bax to kill.
These results were extended to mammalian cells by
showing that, at an early time point, oligomycin quite
effectively inhibited caspase activation and the induction
of apoptotic morphology following Bax overexpression in
293 cells; and p53-induced apoptosis in baby rat kidney
(BRK) cells was also delayed. 
Figure 3
How does Bax cause apoptosis? The
pathway revealed by studies in yeast is shown
with green arrows, and the pathway presumed
to operate in mammalian cells inferred from
the genetics of C. elegans and biochemical
data is shown in white. Red highlights
questions raised by the two yeast studies



















These observations are curious on two levels. Firstly, why
does oligomycin inhibit cell death induced by Bax if Bax-
induced death results from Bcl-xL antagonism (Figure 3)?
Do these results in mammalian cells mean that the func-
tion of the F0F1 ATPase is required for Bax–Bcl-xL het-
erodimerisation, or that Bax–Bcl-xL heterodimerisation is
not required for cell death? Secondly, p53-induced apop-
tosis occurs normally in the absence of Bax [19], so why
oligomycin has an effect on p53-induced apoptosis is
unclear, although one might argue that pro-apoptotic
family members other than Bax can kill by a similar route.
The other approach used was to co-express a mammalian
cDNA library to look directly for suppressors of Bax
killing in yeast [20]. This time, the authors found three
independent clones for the cDNA that they termed Bax
inhibitor 1 (BI-1), an evolutionarily conserved integral
membrane protein containing six or seven membrane-
spanning segments. How BI-1 was able to prevent yeast
death was not determined, but, in transient transfection
assays, BI-1 was also able to inhibit apoptosis of mam-
malian 293 cells induced by serum deprivation, the topoi-
somerase inhibitor etoposide and serine/threonine kinase
inhibitor staurosporine. BI-1 appears to be associated with
the endoplasmic reticulum membrane and the nuclear
envelope. Although BI-1 does not bind to Bax, it is
intriguing that it does bind to Bcl-2 in an interaction that
requires the BH4 domain of Bcl-2. Although BI-1 might
bind to Bcl-2 and thereby co-operate with it to inhibit Bax,
it is difficult to envision how BI-1 operates in yeast, which
lack Bcl-2.
Caution needs to be exercised in imagining how BI-1
might operate, however. The activities of BI-1 in mam-
malian cells are reminiscent of those of Bag-1, a molecule
that was originally identified as a Bcl-2-interacting cell
death inhibitor but has now been shown to be a regulator
of Hsp70; Bag-1 probably only binds indirectly to Bcl-2
via Hsp70, and, furthermore, probably only binds to dena-
tured Bcl-2 [21]. Interpretation of results from over-
expression studies should take into account
considerations such as protein folding and endoplasmic
reticulum function before definitive answers about the
way in which the normally expressed proteins protect
cells can be gained.
Apoptosis research is a difficult business. The ‘final
readout’ for the molecular players in the cell death
program is either life or death, yet many non-physiological
agents cause death, and many molecules which have no
direct role in apoptosis might promote correct folding, pro-
cessing or localisation of bona fide survival factors, confer-
ring an apparent survival advantage. Whatever role is
apportioned to the new players identified as a result of
screening in yeast, we will certainly learn more from them
about the life and death of cells.
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